Skip to main content

Zyloprim Disease Interactions

There are 4 disease interactions with Zyloprim (allopurinol).


Allopurinol (applies to Zyloprim) bone marrow suppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect. The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy. Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.


  1. (2022) "Product Information. Zyloprim (allopurinol)." Glaxo Wellcome

Allopurinol (applies to Zyloprim) dehydration

Moderate Potential Hazard, High plausibility. Applicable conditions: Diarrhea, Vomiting

Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given. Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid. In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline or neutral urine is also desirable.


  1. Landgrebe AR, Nyhan WL, Coleman M (1975) "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med, 292, p. 626-7
  2. Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL (1980) "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med, 92, p. 384-5
  3. McInnes GT, Lawson DH, Jick H (1981) "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis, 40, p. 245-9
  4. (2022) "Product Information. Zyloprim (allopurinol)." Glaxo Wellcome
View all 4 references

Allopurinol (applies to Zyloprim) liver disease

Moderate Potential Hazard, Moderate plausibility.

The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels. Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported. Therapy with allopurinol should be administered cautiously in patients with liver disease. Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.


  1. Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG (1981) "Allopurinol hepatotoxicity." Ann Intern Med, 95, p. 588-90
  2. Raper R, Ibels L, Lauer C, Barnes P, Lunzer M (1984) "Fulminant hepatic failure due to allopurinol." Aust N Z J Med, 14, p. 63-5
  3. Ohsawa T, Ohtsubo M (1985) "Hepatitis associated with allopurinol." Drug Intell Clin Pharm, 19, p. 431-3
  4. (2022) "Product Information. Zyloprim (allopurinol)." Glaxo Wellcome
View all 4 references

Allopurinol (applies to Zyloprim) renal dysfunction

Moderate Potential Hazard, High plausibility.

Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels. Therapy should be initiated at reduced dosages with smaller incremental changes in such patients. Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol. Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases. Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.


  1. Hande K, Reed E, Chabner B (1978) "Allopurinol kinetics." Clin Pharmacol Ther, 23, p. 598-605
  2. Hande KR, Noone RM, Stone WJ (1984) "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med, 76, p. 47-56
  3. (2022) "Product Information. Zyloprim (allopurinol)." Glaxo Wellcome

Zyloprim drug interactions

There are 63 drug interactions with Zyloprim (allopurinol).

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.